Articles

NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.

NanoMab Technology Signs Heads of Terms with OncoBeta

Pfizer has announced that FDA has accepted for filing and granted priority review designation for a new drug application and EMA has accepted the MAA for abrocitinib.

Pfizer Gains FDA and EMA Acceptance for Abrocitinib

Novartis and Molecular Partners are collaborating on the development, manufacture, and commercialization of Molecular Partners’ anti-COVID-19 DARPin program.

Novartis Collaborates with Molecular Partners on Two Anti-COVID-19 Therapies 

The companies have signed a Statement of Intent with Gavi to make 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine available for distribution. 

Sanofi and GSK Agree to Support COVAX with 200 Million COVID-19 Vaccines Doses

Delivery will commence over the course of two months following the EUA and the government will have the ability to purchase up to 650,000 additional vials of the treatment through June 30, 2021 based on product availability and medical need.

Eli Lilly to Provide the US Government with 300,000 vials of its COVID-19 Treatment for $375 Million

The new company will house more than 350 experts and will offer pharmaceutical, life sciences, food and beverage, and manufacturing solutions.

Clarke Solutions, Covex LLC, and Acquire Automation Combine to Form Verista

The Phase III clinical trial of NVX-CoV2373 is expected to be fully enrolled in the UK and will begin in the US and Mexico by the end of November 2020.

Novavax COVID-19 Vaccine Trial Expands Enrollment

Under the partnership, Catalent has ordered visual inspection machines from Stevanato Group to install at its Bloomington, IN and Anagni, Italy facilities to support customer programs.

Catalent and Stevanato Expand Partnership for the Accelerated Delivery of COVID-19 Solutions

The companies will work to provide development strategy consultations, system-building, and clinical trial operations, while lessening development time and reducing risk by centralizing project tasks between companies.

CMIC and SUSMED to Collaborate on Providing Digital Therapeutics Development Services

The new premix can be used with tablets and a range of other solid oral dosage forms.

News